Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis

Allen-Philbey, Kimberley; Stennett, Andrea; Begum, Tahera; Johnson, Austin; Dobson, Ruth; Giovannoni, Gavin; Gnanapavan, Sharmilee; Marta, Mónica; Smets, Ide; Turner, Benjamin; Baker, David; Mathews, Joela; Schmierer, Klaus

doi:10.1016/j.msard.2021.103028

Cited by 24 publications

(23 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Most studies (33/34) included patients vaccinated with the BNT162b2 (Pfizer, n = 33) or the m-1372 (Moderna, n = 12) mRNA vaccines. Only 731 patients receiving recombinant adenoviral vector vaccines ( n = 711 ChAdOx1-nCoV-19, Astrazeneca, n = 20 Ad26.COV2.S, Janssen) and 51 receiving inactivated virus vaccines (BBV152, Bharat) have been described in 7/34 studies [ 33 , 34 , 35 , 36 , 37 , 38 , 39 ]. One study reported disaggregated safety data by vaccine type, although limited to the first half of the vaccination cycle [ 36 ].…”

Section: Literature Reviewmentioning

confidence: 99%

“…Most patients had an established diagnosis with relatively long follow-up data. Five of seven studies where disease duration was reported, included patients living with an autoimmune disorder for an average timespan of 10–15 years [ 33 , 51 , 57 , 60 , 61 , 63 ]. In 12 out of 24 studies with available data (57%), the average patient age ranged between 40 and 55 years.…”

Section: Autoimmune/rheumatic Disordersmentioning

confidence: 99%

“…Data regarding recombinant adenoviral vector vaccines are limited to four studies [ 33 , 35 , 36 , 38 ]. Three of them, including a total of 707 patients, provide information on adverse events after the first dose of the ChAdOx1-nCoV-19 (Astrazeneca) vaccine.…”

Section: Autoimmune/rheumatic Disordersmentioning

confidence: 99%

“…Specifically, compared to patients receiving mRNA vaccines, patients vaccinated with ChAdOx1-nCoV-19 had higher rates of fever, chills, arthralgia/arthritis, fatigue, and headache. Cherian et al and Allen-Philbey et al did not provide disaggregated data by vaccine type, but described two heterogeneous cohorts where 87% and 88% of patients, respectively, were vaccinated with the ChAdOx1-nCoV-19 [ 33 , 38 ]. Consistent with the work by Boekel et al, they found a 18–21% prevalence of fever after the first vaccine dose, which is higher than reported for mRNA vaccines ( Supplementary Table S2 ).…”

Section: Autoimmune/rheumatic Disordersmentioning

confidence: 99%

See 3 more Smart Citations

Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases

et al. 2021

View full text Add to dashboard Cite

Aberrant deployment of the immune response is a hallmark pathogenic feature of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease (COVID-19), possibly accounting for high morbidity and mortality, especially in patients with comorbidities, including immune-mediated disorders. Immunisation with SARS-COV-2 vaccines successfully instructs the immune system to limit viral spread into tissues, mitigate COVID-19 manifestations and prevent its most detrimental inflammatory complications in the general population. Patients with immune-mediated diseases have been excluded from vaccine registration trials, foreclosing the acquisition of specific efficacy and safety data. In this review, we aimed to summarise and critically discuss evidence from real-world studies addressing this issue to provide a comprehensive view of the impact of vaccination practices in patients with allergy, autoimmunity or immunodeficiency. We analysed clinical and laboratory data from 34 studies involving more than 13,000 subjects with various immune disorders who were vaccinated with mRNA- DNA- or inactivated viral particle-based vaccines. These data globally support the safe and effective use of SARS-CoV-2 vaccines in patients with immune-mediated diseases, although patient-tailored strategies to determine vaccination timing, vaccine choice and background therapy management are warranted to optimise vaccination outcomes. More data are needed regarding patients with primary immunodeficiencies.

show abstract

Section: Literature Reviewmentioning

confidence: 99%

Section: Autoimmune/rheumatic Disordersmentioning

confidence: 99%

Section: Autoimmune/rheumatic Disordersmentioning

confidence: 99%

Section: Autoimmune/rheumatic Disordersmentioning

confidence: 99%

See 2 more Smart Citations

Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Eine interviewbasierte Untersuchung von MS-Erkrankten aus Großbritannien fand keine neuen Sicherheitssignale nach Vakzinierung mit dem vektorbasierten ChAdOx1nCoV-19-Impfstoff von Astra Zeneca ( n = 29) und dem BNT162b2-COVID-19 mRNA-Impfstoff von BioNTech/Pfizer ( n = 4) [ 35 ]. Acht der befragten Personen wurden mit Cladribin-Tabletten behandelt.…”

Section: Sars-cov-2-impfung Bei Personen Mit Ms Unter Behandlung Mit Cladribin-tablettenunclassified

Einblicke in die Behandlung der Multiplen Sklerose mit Cladribin-Tabletten seit Beginn der COVID-19-Pandemie

Sellner

2021

psychopraxis. neuropraxis

View full text Add to dashboard Cite

Global burden of vaccine‐associated multiple sclerosis, 1967–2022: A comprehensive analysis of the international pharmacovigilance database

Woo,

Kim,

Park

et al. 2024

Journal of Medical Virology

View full text Add to dashboard Cite

Vaccine‐associated multiple sclerosis (MS) is rare, with insufficient evidence from case reports. Given the scarcity of large‐scale data investigating the association between vaccine administration and adverse events, we investigated the global burden of vaccine‐associated MS and potential related vaccines from 1967 to 2022. Reports on vaccine‐associated MS between 1967 and 2022 were obtained from the World Health Organization International Pharmacovigilance Database (total number of reports = 120 715 116). We evaluated global reports, reporting odds ratio (ROR), and information components (IC) to investigate associations between 19 vaccines and vaccine‐associated MS across 156 countries and territories. We identified 8288 reports of vaccine‐associated MS among 132 980 cases of all‐cause MS. The cumulative number of reports on vaccine‐associated MS gradually increased over time, with a substantial increase after 2020, owing to COVID‐19 mRNA vaccine‐associated MS. Vaccine‐associated MS develops more frequently in males and adolescents. Nine vaccines were significantly associated with higher MS reporting, and the highest disproportional associations were observed for hepatitis B vaccines (ROR 19.82; IC025 4.18), followed by encephalitis (ROR 7.42; IC025 2.59), hepatitis A (ROR 4.46; IC025 1.95), and papillomavirus vaccines (ROR 4.45; IC025 2.01). Additionally, MS showed a significantly disproportionate signal for COVID‐19 mRNA vaccines (ROR 1.55; IC025 0.52). Fatal clinical outcomes were reported in only 0.3% (21/8288) of all cases of vaccine‐associated MS. Although various vaccines are potentially associated with increased risk of MS, we should be cautious about the increased risk of MS following vaccination, particularly hepatitis B and COVID‐19 mRNA vaccines, and should consider the risk factors associated with vaccine‐associated MS.

show abstract

Experience with the COVID-19 AstraZeneca vaccination in people with multiple sclerosis

Cited by 24 publications

References 10 publications

Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases

Challenges to Vaccination against SARS-CoV-2 in Patients with Immune-Mediated Diseases

Einblicke in die Behandlung der Multiplen Sklerose mit Cladribin-Tabletten seit Beginn der COVID-19-Pandemie

Global burden of vaccine‐associated multiple sclerosis, 1967–2022: A comprehensive analysis of the international pharmacovigilance database

Contact Info

Product

Resources

About